PP-C8

• Description:

  PP-C8 is a potent and selective PROTAC CDK12-Cyclin K degrader. PP-C8 induces CDK12-Cyclin K degradation with DC50s of 416 and 412 nM for CDK12 and Cyclin K, respectively. PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC) [1].

• UNSPSC:

  12352005

• Target:

  CDK; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pp-c8.html

• Purity:

  99.99

• Solubility:

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CC (N1C=NC2=C1N=C (N=C2NCC3=NC4=CC (F) =C (C=C4N3) NCCCCCCCCNC (COC5=C6C (N (C (C6=CC=C5) =O) C7CCC (NC7=O) =O) =O) =O) N8CCOCC8) C

• Molecular Formula:

  C43H51FN12O7

• Molecular Weight:

  866.94

• References & Citations:

  [1]Tian Niu, et al. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor. Eur J Med Chem. 2022 Jan 15;228:114012.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  3032108-74-7